# Norroy Bioscience

Source: https://onco.cc/companies/norroy-bioscience/  
OnCo record `norroy-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Norroy Bioscience is a China-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the PSMA-targeted radiopharmaceuticals 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer.

## Summary

Norroy Bioscience is a clinical-stage company developing therapeutic and diagnostic radiopharmaceuticals together with automated synthesis systems for their manufacture. Its candidates are led by PSMA-targeted 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer and CAIX-targeted tracers in kidney cancer. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT06383052 (phase 1/2, A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC), NCT07615101 (phase 3, Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in...) and NCT07649122 (phase 3, This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imagin...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Norroy Bioscience Co., LTD
- Tags: ctgov-sponsor
- HQ: Wuxi, Jiangsu
- Type: radiopharma
- Website: https://www.norroybiopharm.com/

## Sources

- Official website: https://www.norroybiopharm.com/
- ClinicalTrials.gov: trials led by Norroy Bioscience: https://clinicaltrials.gov/search?lead=Norroy%20Bioscience%20Co.%2C%20LTD

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC](https://onco.cc/trials/nct06383052/), [Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.](https://onco.cc/trials/nct07615101/), [This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.](https://onco.cc/trials/nct07649122/)

---
JSON: https://onco.cc/api/v1/entities/norroy-bioscience.json